Pharmacogenetic Testing: Genotypes, Phenotypes, and Clinical Application in Psychopharmacology von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

Name: Pharmacogenetic Testing: Genotypes, Phenotypes, and Clinical Application in Psychopharmacology
Uploaded: 2025-11-11
Duration: 7 min 2 s
Description: Der Vortrag „Pharmacogenetic Testing: Genotypes, Phenotypes, and Clinical Application in Psychopharmacology“ von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE ist Bestandteil des Kurses „Hormonal and Genetic Influences in Psychopharmacology“.

Über den Vortrag

Der Vortrag „Pharmacogenetic Testing: Genotypes, Phenotypes, and Clinical Application in Psychopharmacology“ von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE ist Bestandteil des Kurses „Hormonal and Genetic Influences in Psychopharmacology“.

Quiz zum Vortrag

Pharmacodynamic gene-drug interactions occur when an individual's genotype impacts ...?

...how a drug produces its effect on the body.
...how quickly the body absorbs a drug into circulation.
...the rate at which a drug is eliminated from the body.
...how a drug is distributed through the bloodstream.
...how a drug binds to plasma proteins in the blood.

A patient with a long-long genotype for SLC6A4 would be expected to experience ...?

...a good response to serotonergic medications.
...a diminished response to serotonergic medications.
...minimal or no response to serotonergic medications.
...increased side effects from serotonergic medications.
...paradoxical worsening of symptoms on SSRIs.

The four cytochrome P450 enzymes that are most important for psychopharmacology are CYP1A2, CYP3A4, CYP2D6, and CYP2C19 because they ...?

...cover approximately 80% of psychotropic medications.
...are responsible for all drug absorption processes.
...determine the risk of serious adverse drug reactions.
...control the synthesis of neurotransmitters in the brain.
...regulate how quickly drugs cross the blood-brain barrier.

A patient classified as a poor metabolizer for a specific enzyme pathway should be ...?

...started at low doses and titrated slowly due to reduced drug breakdown.
...given standard medication doses as they process drugs normally.
...prescribed increased doses because they eliminate drugs too quickly.
...started at higher doses and titrated down based on response.
...given extended-release formulations to compensate for metabolism.

Comprehensive treatment outcomes for psychiatric conditions depend on ...?

...optimal medication selection combined with psychotherapy, social support, and addressing psychosocial determinants.
...genetic testing alone to determine the correct medication regimen.
...psychotherapy exclusively without any medication management interventions.
...medication dosing based solely on metabolizer status classifications.
...pharmacological interventions while minimizing non-medical treatment approaches.

Diese Kurse könnten Sie interessieren

Psychopharmacology (APRN)

Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

(1)

~~3,10 € mtl.~~ 1,99 € mtl.

Sie sparen 36 %

Hormonal and Genetic Influences in Psychopharmacology

Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

(1)

~~1,00 € mtl.~~ 9,90 €

Sie sparen 1 %

Dozent des Vortrages Pharmacogenetic Testing: Genotypes, Phenotypes, and Clinical Application in Psychopharmacology

Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

Dr. Melissa Kalensky, FNP-BC, PMHNP-BC, CNE is dual-certified as a Family Nurse Practitioner and a Psychiatric Mental Health Nurse Practitioner.

She specializes in primary care, community health, and integrated behavioral healthcare. Her expertise spans trauma-informed care and psychiatry across all age groups, from children to adults.

At Lecturio, she teaches psychopharmacology to advanced practice providers, helping to bridge the gap between psychiatric and primary care practice.

alle anzeigen Weniger anzeigen

Kundenrezensionen

(1)
5,0 von 5 Sternen

5 Sterne		5
4 Sterne		0
3 Sterne		0
2 Sterne		0
1 Stern		0

oder

Vortrag freischalten 1,00 €